APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
1 Year Est. Return
+195%
AUM
$936M
AUM Growth
+$589M
(+170%)
Holding
67
Top Buys
| 1 | +$122M | |
| 2 | +$37.6M | |
| 3 | +$29.9M | |
| 4 |
JBIO
Jade Biosciences
JBIO
|
+$20.3M |
| 5 |
Enliven Therapeutics
ELVN
|
+$18.3M |
Top Sells
| 1 | +$10.4M | |
| 2 | +$8.35M | |
| 3 | +$7.81M | |
| 4 |
Agilent Technologies
A
|
+$5.65M |
| 5 |
Pfizer
PFE
|
+$5.07M |
Sector Composition
| 1 | Healthcare | 99.4% |
| 2 | Consumer Staples | 0.39% |
| 3 | Consumer Discretionary | 0.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Savara
SVRA
$1.07B
| $262K | 0.03% |
+50,000
|
|
||
52
Trevi Therapeutics
TRVI
$2.01B
| $171K | 0.02% |
+13,320
|
|
||
|
53
Agilent Technologies
A
$38.2B
| – | – |
-41,500
|
|
||
54
Acadia Healthcare
ACHC
$2.13B
| – | – |
-169,000
|
|
||
55
Alnylam Pharmaceuticals
ALNY
$40.3B
| – | – |
-21,000
|
|
||
56
Cigna
CI
$73.4B
| – | – |
-11,600
|
|
||
57
Cencora
COR
$52.4B
| – | – |
-9,400
|
|
||
58
Danaher
DHR
$129B
| – | – |
-17,000
|
|
||
59
HealthEquity
HQY
$7.36B
| – | – |
-16,900
|
|
||
60
Insmed
INSM
$23.2B
| – | – |
-17,700
|
|
||
61
IQVIA
IQV
$30.4B
| – | – |
-4,400
|
|
||
62
Integer Holdings
ITGR
$3.03B
| – | – |
-29,800
|
|
||
63
McKesson
MCK
$89.2B
| – | – |
-9,520
|
|
||
|
NVO
64
Novo Nordisk
NVO
$202B
| – | – |
-67,300
|
|
||
|
65
Pfizer
PFE
$149B
| – | – |
-203,600
|
|
||
66
Thermo Fisher Scientific
TMO
$183B
| – | – |
-6,700
|
|
||
67
Waters Corp
WAT
$37.7B
| – | – |
-8,100
|
|